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The liver constitutes a relatively immu-
noprivileged microenvironment, as 
demonstrated by the fact that it accepts 
antigenic material (bacterial components 
and food antigens through blood supply 
from the portal vein) in the absence of 
immune responses, as well as by the rela-
tively high rate of acceptance of allogeneic 
transplants, in many species including 
humans.1 In addition, the liver is the 
site of persistence of common pathogens 
including the hepatitis B and C viruses, 
which exploit the relative immunologi-
cal tolerance of this organ.1 Cancer cells 
may also take advantage of the immu-
noregulatory mechanisms that are estab-
lished in the liver. Indeed, the liver is one 
of the most common sites of metastatic 
dissemination.
Hepatocellular carcinoma (HCC) and 
liver metastases from colorectal cancer 
(LM-CRC) are the main malignancies 
affecting the liver and are among the most 
common cancers and leading causes of 
cancer mortality.2,3 Curative treatment 
options, like liver resection, liver trans-
plantation and image-guided percuta-
neous ablation, are limited to very early 
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stages of the malignant disease and can-
not prevent recurrence. In addition, HCC 
is extremely resistant to chemotherapy. 
Immunotherapy represents an attractive 
alternative approach because of the speci-
ficity and memory of the immune system. 
The main goal of anticancer immuno-
therapy is to induce a strong immune 
response that can efficiently attack and 
eliminate tumor cells. Several attempts to 
design such a therapy have been evaluated 
in clinical trials (reviewed in refs. 3,4). 
However, although vaccination therapies 
induced detectable numbers of circulating 
tumor-specific T cells, they have shown 
limited efficacy in terms of disease pro-
gression and patient survival. The failure 
of immunotherapeutic approaches against 
hepatic neoplasms may be related to intra-
hepatic immunological tolerance, but the 
tumor microenvironment can also play a 
major role in hampering the antitumor 
immunity, as it has been shown in many 
others oncological settings.5,6
Recently, in patients affected by 
primary or metastatic liver cancer, we 
observed that the high frequency of CD8+ 
T cells, natural killer (NK) and NKT cells 
that are detected in normal liver tissue are 
significantly decreased in the tumor bed, 
while the amount of intratumoral CD4+ 
T cells is increased. Furthermore, we 
found that tumor-infiltrating CD4+ and 
CD8+ T cells display an impaired antitu-
mor response.7 These dramatic changes 
in the composition and function of 
intratumoral lymphocytes indicate that 
hepatic tumors generate an immunoper-
missive environment, which may contrib-
ute to tumor progression. Importantly, 
we showed that CD4+FOXP3+ regulatory 
T cells (Tregs) accumulate in the tumors 
of these patients. Tumor-infiltrating 
Tregs (TiTreg) were highly activated 
as compared with Tregs isolated from 
tumor-free liver tissue, and showed a 
potent capacity to inhibit tumor-specific 
T-cell responses ex vivo as compared with 
circulating Tregs from the same patient. 
Therefore, we conclude that Tregs locally 
suppress antitumor immunity within 
hepatic tumors.
The mechanisms responsible for Tregs 
accumulation in hepatic tumors are not 
well elucidated, but a role for specific 
chemokines like CCL-20 and 22 has 
recently, we reported the accumulation of CD4+FOXP3+ regulatory t cells (tregs) within the tumor mass of patients bearing 
liver cancer. tumor-infiltrating tregs (titreg) are active and potent suppressors of antitumor immunity. Importantly, 
treatment with GItrL reduced the immunosuppression mediated by titreg.
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the immunosuppressive activity of TiTreg 
derived from both HCC and LM-CRC 
lesions. Even though the mechanism by 
which GITRL exerts immunostimula-
tory effects is still elusive, it has been sug-
gested that it can act either by abrogating 
the immunosuppressive functions of Tregs 
or by rendering effector T cells resistant 
to Treg-mediated suppression.10 Of note, 
GITR expressed on activated conventional 
T cells acts as a costimulatory molecule.10 
These observations suggest that modulat-
ing GITR may serve as an adjuvant for 
the immunotherapy of hepatic tumors, 
restoring the effector functions of CD4+ 
and CD8+ T cells and enhancing tumor-
specific T-cell activity.
Our data not only provide new insights 
into the pathogenesis of hepatic malig-
nancies, but also identify a potentially 
immunotherapeutic efforts to induce effi-
cient antitumor immunity in liver cancer 
patients. Manipulation of Treg function 
may therefore be an attractive option to 
improve the outcome of immunotherapy 
in patients with hepatic cancer. In our 
study, we found that Tregs infiltrating 
both HCC and LM-CRC lesions are char-
acterized by an elevated expression of the 
glucocorticoid-induced tumor necrosis 
factor receptor (GITR) and the inducible 
T-cell costimulator (ICOS) as compared 
with Tregs purified from tumor-free liver 
tissue and the blood. Similar findings have 
been reported for breast tumors.8 GITR 
and ICOS are regulators of the immuno-
suppressive function of Tregs and can be 
targeted for immunotherapeutic interven-
tions. In our study, we showed that a soluble 
GITR ligand (GITRL) partially prevents 
been reported.6,8 In our study, we showed 
that TiTreg, as found within LM-CRC, 
actively proliferate,7 indicating that local 
expansion contributes to the accumulation 
of TiTreg observed in this setting. In con-
trast, Tregs infiltrating HCC lesions seem 
not to proliferate, and it has been pro-
posed that tumor-derived CCL-20 plays 
a major role in promoting the accumula-
tion of Tregs in HCC lesions.9 Therefore, 
chemokine-mediated migration and local 
expansion are two important mechanisms 
involved in the accumulation of Tregs in 
hepatic tumors (Fig. 1). These findings 
point to a tumor-specific, rather than to 
an organ-specific, Treg accumulation in 
primary and secondary liver neoplasms.
High frequencies of TiTreg and 
their potent immunosuppressive activ-
ity may have interfered with the 
Figure 1. Immunoregulation in hepatic cancer. the liver contains significant numbers of lymphocytes with a dominant presence of CD8+ t cells. In 
contrast, liver neoplasms are characterized by a dominant population of CD4+ t cells, which include an important proportion of activated CD4+FOXP3+ 
regulatory t cells (tregs). Both conventional CD4+ and CD8+ t cells found within the tumor lesion are functionally impaired. tregs can either be 
recruited to the tumor tissue by specific chemokines, or expand locally. tumor-infiltrating tregs (titreg) potently suppress tumor-specific t cells, for 
instance by expressing CtLA-4 as well as by producing immunosuppressive molecules like interleukin (IL)-10, IL-35 and transforming growth factor 
β (tGFβ). tregs infiltrating hepatic tumors express high levels of glucocorticoid-induced tumor necrosis factor receptor (GItr) and inducible t-cell 
costimulator (ICOs), and the administration of a soluble GItr ligand (GItrL) partially abrogates the immunosuppression mediated by titreg. targeting 
the immunosuppressive functions of titreg may augment the efficacy of immunotherapeutic approaches like dendritic cell (DC)-based vaccination.
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novel therapeutic target. Based on these 
findings, we propose that reversing the 
immunosuppressive tumor microenvi-
ronment with GITRL or other molecules 
that may affect the suppressive capacity of 
TiTreg, like ICOS and CTLA-4 blocking 
antibodies, is critical to restore local anti-
tumor immune responses. Therefore, 
immunotherapeutic approaches, such as 
dendritic cell (DC)-based vaccination or 
tumor-specific T cell transfer, may benefit 
from the targeting of TiTreg to prevent 
the local suppression of antitumor T-cell 
responses (Fig. 1).
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